Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Receivables (2019 - 2025)

Historic Receivables for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to $2.5 million.

  • Inmune Bio's Receivables rose 4897.22% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 4897.22%. This contributed to the annual value of $1.4 million for FY2024, which is 4230.14% down from last year.
  • Inmune Bio's Receivables amounted to $2.5 million in Q3 2025, which was up 4897.22% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Inmune Bio's Receivables registered a high of $3.7 million during Q2 2024, and its lowest value of $100000.0 during Q1 2021.
  • Moreover, its 5-year median value for Receivables was $904500.0 (2021), whereas its average is $1.2 million.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 9655.17% in 2021, then surged by 10000.0% in 2022.
  • Over the past 5 years, Inmune Bio's Receivables (Quarter) stood at $400000.0 in 2021, then crashed by 75.0% to $100000.0 in 2022, then soared by 2342.0% to $2.4 million in 2023, then tumbled by 42.3% to $1.4 million in 2024, then surged by 74.88% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.6 million for Q2 2025, and $1.4 million during Q1 2025.